PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
Ohio and Denver, Colorado--(Newsfile Corp. - July 21, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announces that it has received government sanctioned, formal written approval to manufacture PsyBio's proprietary biosynthetic tryptamines."PsyBio has...
2023-07-21 8:00 AM EDT
PsyBio Announces Closing of Third Tranche of Private Placement
Ohio and Denver, Colorado--(Newsfile Corp. - April 20, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the third tranche of its previously announced non-brokered private placement offering of units of...
2023-04-20 5:36 PM EDT
PsyBio Announces Panel Participation on NextGen Psychedelics at Benzinga Cannabis Capital Conference
Ohio and Denver, Colorado--(Newsfile Corp. - April 6, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that PsyBio CEO Evan Levine will be participating on the panel NextGen Psychedelics and conducting one-on-one meetings, at...
2023-04-06 9:12 AM EDT
PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit
Miami, Florida--(Newsfile Corp. - March 13, 2023) - Evan Levine, CEO and Founder of PsyBio Therapeutics, won Best Pitch at Kahner Global's Cannabis & Psychedelics Investment Summit last week. Levine was awarded for his visionary approach to developing next-generation therapies for mental health conditions using cutting-edge research and development methods.The Summit is an annual conference that brings together some of the most influential leaders in the cannabis and psychedelics industries....
2023-03-13 7:00 AM EDT
PsyBio Announces Closing of Second Tranche of Private Placement
Ohio and Denver, Colorado--(Newsfile Corp. - January 13, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the second tranche of its previously announced non-brokered private placement offering of units...
2023-01-13 6:05 PM EST
PsyBio Announces Appointment of Ian Wisenberg to Board of Directors
Ohio and Denver, Colorado--(Newsfile Corp. - January 10, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused on the discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent...
2023-01-10 12:16 PM EST
PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update
Ohio and Denver, Colorado--(Newsfile Corp. - January 5, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the first tranche of its previously announced non-brokered private placement offering of units...
2023-01-05 8:30 AM EST